Related Experiment Video
Updated: Oct 25, 2025
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
Cell Population Data and Serum Polyclonal Immunoglobulin Free Light Chains in the Assessment of COVID-19 Severity
Milena Małecka-Giełdowska1,2, Maria Fołta3, Agnieszka Wiśniewska1,2
1Department of Laboratory Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.
Insights
Free light chain (FLC) κ measurement effectively distinguishes severe COVID-19 from nonsevere cases. This blood test offers high sensitivity and specificity for risk stratification in COVID-19 patients.
Area of Science:
- Immunology
- Infectious Diseases
- Clinical Chemistry
Background:
- Differentiating severe from nonsevere COVID-19 is crucial for healthcare resource allocation.
- Current methods for COVID-19 severity assessment require improvement for better patient management.
Purpose of the Study:
- To evaluate the utility of complete blood count (CBC) parameters and serum free light chain (FLC) concentrations in stratifying COVID-19 patient risk.
- To determine if FLC analysis can aid in distinguishing severe from nonsevere COVID-19.
Main Methods:
- A cohort of 735 patients (COVID ICU, COVID non-ICU, non-COVID ICU) underwent CBC analysis.
- Serum FLC (κ and λ) concentrations were measured in 133 patients.
- Statistical analysis, including AUC, sensitivity, specificity, and odds ratio, was performed.
Main Results:
- COVID ICU patients exhibited distinct neutrophil and lymphocyte characteristics.
- Significant differences in κ and λ FLC concentrations were observed between severe (COVID ICU) and nonsevere (COVID non-ICU) COVID-19 patients.
- FLC κ measurement demonstrated high accuracy (AUC=0.7669), with 86.67% sensitivity and 93.33% specificity, in distinguishing severe COVID-19.
Conclusions:
- Serum FLC concentration measurements are valuable tools for differentiating severe from nonsevere COVID-19.
- FLC κ levels show significant potential for risk stratification in COVID-19 patients.
- This approach can enhance healthcare efficiency by identifying high-risk individuals.
Abstract:
Distinguishing between severe and nonsevere COVID-19 to ensure adequate healthcare quality and efficiency is a challenge for the healthcare system. The aim of this study was to assess the usefulness of CBC parameters together with analysis of FLC serum concentration in risk stratification of COVID-19.
Materials And Methods:
CBC was analyzed in 735 COVID ICU, COVID non-ICU, and non-COVID ICU cases. FLC concentration was analyzed in 133 of them.
Results:
COVID ICU had neutrophils and lymphocytes with the greatest size, granularity, and nucleic acid content. Significant differences in concentrations of κ and λ FLCs were shown between COVID ICU and COVID non-ICU. However, no difference was found in the κ/λ ratio between these groups, and the ratio stayed within the reference value, which indicates the presence of polyclonal FLCs. FLC κ measurement has significant power to distinguish between severe COVID-19 and nonsevere COVID-19 (AUC = 0.7669), with a sensitivity of 86.67% and specificity of 93.33%. The κ coefficients' odds ratio of 3.0401 was estimated.
Conclusion:
It can be concluded that the results obtained from the measure of free light immunoglobulin concentration in serum are useful in distinguishing between severe and nonsevere COVID-19.
